NZ729012B2 - Recombinant modified vaccinia virus ankara (mva) filovirus vaccine - Google Patents

Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

Info

Publication number
NZ729012B2
NZ729012B2 NZ729012A NZ72901215A NZ729012B2 NZ 729012 B2 NZ729012 B2 NZ 729012B2 NZ 729012 A NZ729012 A NZ 729012A NZ 72901215 A NZ72901215 A NZ 72901215A NZ 729012 B2 NZ729012 B2 NZ 729012B2
Authority
NZ
New Zealand
Prior art keywords
seq
nucleic acid
acid encoding
set forth
sequence set
Prior art date
Application number
NZ729012A
Other versions
NZ729012A (en
Inventor
Ulrike Dirmeier
Jurgen Hausmann
Hubertus Hochrein
Henning Lauterbach
Robin Steigerwald
Ariane Volkmann
Original Assignee
Bavarian Nordic A/S
Filing date
Publication date
Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S
Priority claimed from PCT/EP2015/070161 external-priority patent/WO2016034678A2/en
Publication of NZ729012A publication Critical patent/NZ729012A/en
Publication of NZ729012B2 publication Critical patent/NZ729012B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the invention relates to recombinant MVA vector comprising a Marburg (MARV) envelope glycoprotein, a Zaire Ebola virus (ZEBOV) envelope glycoprotein, a Sudan Ebola virus (SEBOV) envelope glycoprotein and an Ebola virus Ivory Coast nucleoprotein.

Claims (6)

1. A method of inducing an immune se in a non-human t, the method comprising administering to the non-human subject the recombinant MVA vector comprising: a first nucleic acid encoding at least one immunogenic protein of a MARV envelope glycoprotein; a second nucleic acid encoding an immunogenic protein of Zaire Ebola virus (ZEBOV) envelope glycoprotein; a third nucleic acid encoding an immunogenic protein of Sudan Ebola virus (SEBOV) envelope glycoprotein; and a fourth nucleic acid encoding an immunogenic protein of Ebola virus Ivory Coast nucleoprotein.
2. The method of claim 1, wherein the MARV envelope glycoprotein is ength MARVMusoke envelope glycoprotein.
3. The method of claim 2, wherein the first nucleic acid encodes an genic protein comprising the sequence set forth in SEQ ID NO:6.
4. The method of claim 3, n the first nucleic acid comprises the sequence set forth in SEQ ID NO:5. 5. The method of claim 1, wherein the recombinant MVA vector comprises a nucleic acid encoding an immunogenic n having a sequence selected from the group ting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, SEQ ID NO:31, and SEQ ID NO:37. 6. The method of claim 1, wherein the recombinant MVA vector comprises a nucleic acid encoding an immunogenic protein comprising the sequence set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, or SEQ ID NO:31. 7. The method of claim 6, wherein said nucleic acid comprises the sequence set forth in SEQ ID NO;5, SEQ ID NO:19, SEQ ID NO:28, or SEQ ID NO;30. 8. The method of any one of claims 1 to 7, wherein the administration provides tive immunity or a protective immune response in the non-human subject. 9. The method of claim 1, n the recombinant MVA vector comprises at least one nucleic acid encoding the sequences set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, and SEQ ID NO:31. 10. The method of any one of claims 1 to 9, wherein the recombinant MVA further comprises a nucleic acid encoding CD40L. 11. The method of claim 10, wherein the CD40L comprises the amino acid sequence set forth in SEQ ID NO:10. 12. The method of claim 11, wherein the nucleic acid encoding CD40L comprises the sequence set forth in SEQ ID NO:9. 13. Use of a recombinant MVA vector in the manufacture of a medicament for inducing an immune response in a human subject, the inant MVA vector comprising: a first nucleic acid encoding at least one immunogenic protein of a MARV envelope glycoprotein; a second nucleic acid encoding an immunogenic protein of Zaire Ebola virus (ZEBOV) envelope glycoprotein; a third nucleic acid encoding an genic protein of Sudan Ebola virus (SEBOV) envelope glycoprotein; and a fourth nucleic acid ng an immunogenic protein of Ebola virus Ivory Coast nucleoprotein. 14. The use of claim 13, wherein the MARV pe glycoprotein is full-length MARVMusoke envelope glycoprotein. 15. The use of claim 14, wherein the first nucleic acid encodes an immunogenic protein comprising the sequence set forth in SEQ ID NO:6. 16. The use of claim 15, wherein the first nucleic acid comprises the sequence set forth in SEQ ID NO:5. 17. The use of claim 13, wherein the recombinant MVA vector ses a nucleic acid ng an immunogenic protein having a sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, SEQ ID NO:31, and SEQ ID NO:37. 18. The use of claim 13, wherein the recombinant MVA vector ses a nucleic acid encoding an immunogenic protein comprising the sequence set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, or SEQ ID NO:31. 19. The use of claim 18, wherein said c acid comprises the sequence set forth in SEQ ID NO;5, SEQ ID NO:19, SEQ ID NO:28, or SEQ ID NO;30. 20. The use of any one of claims 13 to 19, wherein the medicament is formulated to provide protective immunity or a protective immune response in the human t. 21. The use of claim 13, n the recombinant MVA vector comprises at least one nucleic acid encoding the sequences set forth in SEQ ID NO:6, SEQ ID NO:20, SEQ ID NO:29, and SEQ ID NO:31. 22. The use of any one of claims 13 to 21, wherein the recombinant MVA further comprises a nucleic acid encoding CD40L. 23. The use of claim 22, wherein the CD40L comprises the amino acid sequence set forth in SEQ ID NO:10. 24. The use of claim 23, wherein the nucleic acid encoding CD40L comprises the sequence set forth in SEQ ID NO:9. 5a: lama: $83 3.3 3 Ema. E 83% :3: 3 xs?xaum wx?ma? gamed 5th $3: 59¢ 3mm: $328283 38$ 330 auahmgem 3359222 25 3mm: a3: “Nam: 5mm 5.30 Cm?hm 555 5.8 .3ng 5.25 ~93me sis: :33 :35 :33 >52 555m Embm 55% :23”. swam 55% ‘ 555 :35 £93 555 528 5E5 o2 55% 5&5 £55 Enzm 9.: ,,, a , , mm a, N5 x 2: 2: wats?enm magEmua?mE mai?cam “much. Wakg?o?m mEEanw watmuk?mE mEEmEQw «LEN 5.92 233.3% =3wa mm :Emém «~10qu @5900 Tlllllll.Eva 92.4 E35285. 93w 50.25 "Emmy ’ Emmanuc?uzz m2£ugwmw$n?a?w? WEEUmhmaaz ”mmuamsgm ".30 uEmm??m Ea: 33:5 mmwm??u. 339mg. mag gems, ”w mam} mEEEgoEozz am HmcEwmm %%%@§%,. mwmwé m m2 ”mc?mmm my e 4% ma?au Emumu??umz EzwccaEaU mc?auéag mama mama mx0m=§<$t<§iw m..."— 8:3 $3 AHV 3»:va dummmi mm. m«0nz§<.>t$\0mm~d0 5:: mKE man. AHV owa on ”—0— Jowmmww .- >Omm u ¢bud o z c Ein— :35 a. u.- mun. _>_ mm 2%: 8%: mmNNZmE-<>_>_ no axe 0 .- no :33 axe no u a. 3.5% u 2:33 .53 o on o u as o on o u. u a no o m5 5.3% o o. o on >9. to n_x0_ :IEmm a.
5. n no o no o. 3.5% aucicssom?iu o $3 o a. t mi o. oo- o to on o. so m0. o o axe on oo o - no u o- on o n o u. o o o o no wmmgn. u a uuziussom?du no _u_._n_ Um <¢mNZmE-<>_>_ om n_u_ 2%: Zm.-<>_>_ 8%: >n_u_ Fu— “em". mewMG.‘ «.23 mi «9/ mi om?xzma mum: EV mewmg «.0. 62: AER: $th $2: E/ 3:2 _mEn_ wk. mawm .22 $
6. mi // ._.n_0 nm?xzma 05 mu.”—
NZ729012A 2015-09-03 Recombinant modified vaccinia virus ankara (mva) filovirus vaccine NZ729012B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045538P 2014-09-03 2014-09-03
US201462055154P 2014-09-25 2014-09-25
PCT/EP2015/070161 WO2016034678A2 (en) 2014-09-03 2015-09-03 Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

Publications (2)

Publication Number Publication Date
NZ729012A NZ729012A (en) 2023-12-22
NZ729012B2 true NZ729012B2 (en) 2024-03-26

Family

ID=

Similar Documents

Publication Publication Date Title
Frederiksen et al. The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies
US20240091338A1 (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
AU2015310909B2 (en) Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine
CN105980570B (en) CMV vaccines
HRP20210608T1 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
MX2022009962A (en) Vaccines and uses thereof to induce an immune response to sars-cov2.
AR038596A1 (en) VIRUS EXPRESSION SYSTEMS FOR REINFORCING RECOMBINANTS AND VACCINES THAT INCLUDE OLD HETEROLOGIES DERIVED FROM METAPNEUMOVIRUS
MX2020002876A (en) Method for the safe induction of immunity against rsv.
WO2016109792A8 (en) Novel multivalent nanoparticle-based vaccines
JP2008500399A5 (en)
JP2014506785A5 (en)
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
WO2018097603A3 (en) Middle east respiratory syndrome coronavirus s protein immunogenic composition and method for preparing same
EP2552490A4 (en) Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
Lawrence et al. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses
MX2021004907A (en) 4/91 ibv vaccine with heterologous spike protein.
NZ729012B2 (en) Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
BRPI0416916A (en) promoters for expression in modified vaccinia virus ankara
JP2020522249A5 (en)
PH12018500468A1 (en) Fusion protein
CA2935341A1 (en) Poxvirus-plasmodium recombinants, compositions containing such recombinants, uses thereof, and methods of making and using same
PH12020500194A1 (en) Malaria vaccine
MX2023014564A (en) Temperature-controllable, self-replicating rna vaccines for viral diseases.
JP6373601B2 (en) Peptides that induce antibodies with neutralizing activity against Akabane virus